MorphoSys grants ContraFect rights to antibodies to treat infectious diseases developed using MorphoSys' HuCAL Platinum antibody library and AutoCAL automated antibody identification method

MorphoSys AG

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

ContraFect Corp.

U.S. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced